The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...

European shares closed at a new peak on Tuesday, powered by gains in the healthcare sector, after heavyweight Novo Nordisk ...

Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.

Now, it’s worth noting Stock Advisor’s total average return is 975 % — a market-crushing outperformance compared to 193% for ...

Eli Lilly stock fell on Tuesday after Novo Nordisk, its rival in diabetes and weight-loss drugs, secured regulatory approval ...

Novo Nordisk secured U.S. regulatory approval for its weight-loss pill, giving the Danish drugmaker a shot at reclaiming ...

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...